Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer

Lukey, M. J., Cluntun, A. A., Katt, W. P., Lin, M. J., Druso, J. E., Ramachandran, S., Erickson, J. W., Le, H. H., Wang, Z. E., Blank, B., Greene, K. S., Cerione, R. A. (October 2019) Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer. Cell Rep, 29 (1). 76-88 e7. ISSN 2211-1247

PDF Lukey_CellReports.pdf - Published Version Download (3MB)

Abstract

Efforts to target glutamine metabolism for cancer therapy have focused on the glutaminase isozyme GLS. The importance of the other isozyme, GLS2, in cancer has remained unclear, and it has been described as a tumor suppressor in some contexts. Here, we report that GLS2 is upregulated and essential in luminal-subtype breast tumors, which account for >70% of breast cancer incidence. We show that GLS2 expression is elevated by GATA3 in luminal-subtype cells but suppressed by promoter methylation in basal-subtype cells. Although luminal breast cancers resist GLS-selective inhibitors, we find that they can be targeted with a dual-GLS/GLS2 inhibitor. These results establish a critical role for GLS2 in mammary tumorigenesis and advance our understanding of how to target glutamine metabolism in cancer.

Item Type:	Paper
Subjects:	bioinformatics > genomics and proteomics > genetics & nucleic acid processing > DNA, RNA structure, function, modification > DNA methylation diseases & disorders > cancer > cancer types > breast cancer diseases & disorders > cancer > drugs and therapies organs, tissues, organelles, cell types and functions > organs types and functions > metabolism
CSHL Authors:	Lukey, Michael
Communities:	CSHL labs > Lukey lab
Depositing User:	Adrian Gomez
Date:	1 October 2019
Date Deposited:	27 Jan 2020 16:49
Last Modified:	27 Jan 2020 16:49
PMCID:	PMC6939472
Related URLs:	Publisher
URI:	https://repository.cshl.edu/id/eprint/38935

Actions (login required)

Administrator's edit/view item